Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines

Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv41–iv51
Authors: A. Hochhaus, S. Saussele, G. Rosti, F.-X. Mahon, J. J. W. M. Janssen, H. Hjorth-Hansen, J. Richter and C. Buske

The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia provide updated treatment recommendations including the monitoring and management of side effects, as well as a new treatment algorithm for chronic phase chronic myeloid leukaemia patients.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.